SUMMARY In a prospective study, 100 women with recurrent vaginal candidosis were treated with miconazole, using two 100 mg vaginal pessaries a day for one week, then one pessary twice a week for three months followed by one pessary a week for a further three months. Fifty four women elected to continue using one pessary a week for longer than six months.
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Symptomatic vaginal candidosis did not occur in any patient during regular maintenance treatment. Of the 46 women who discontinued treatment before six months, however, 22 had a recurrence.
Maintenance prophylactic treatment with miconazole pessaries appears to be an acceptable and effective method of preventing recurrent episodes of vaginal candidosis.
Vaginal candidosis is the commonest genital infection in women, and a proportion of women go on to develop recurrent disease. It is not known why some women develop recurrent attacks, although the pathogenicity of Candida albicans in the vagina was recently the subject of extensive review.' One of the interesting theories proposed is that recurrent vaginal candidosis may be associated with disordered carbohydrate metabolism,2 perhaps locally, but no single cause has yet been defined.
Acute vaginal candidosis can be treated simply and effectively with one of several antifungal agents, but the acute treatment regimens used seem not to influence the development of recurrent disease. Managing patients with recurrent disease has been less well studied than treatment of acute episodes. In a double blind placebo controlled study, Davidson We studied 183 women with recurrent vaginal candidosis who received prophylactic courses of miconazole pessaries, and in this paper we report our findings in the first 100 to have been followed up for one year.
Patients and methods

STUDY POPULATION
We studied 100 women aged 18 to 45, who were outpatients at the department of genitourinary medicine of this hospital. All had recurrent vaginal candidosis, which was defined as at least two culture proved episodes in the previous 12 months. At the time of entry to the study all patients had acute vaginal candidosis, with symptoms of itching and soreness, signs of vulvovaginitis, and a positive candida culture. We excluded patients with mixed vaginal infections, known hypersensitivity to imidazole antifungals, or who had received antifungal treatment in the 14 days Recurrent vaginal candidosis: prospective study ofeffectiveness ofmaintenance miconazole treatment preceding entry to the study. We also excluded pregnant women and those intending to become pregnant during the course of the study. in their twenties or thirties, and most used oral contraceptives. Two had underlying disease other than diabetes; one had a history of renal disease and one of ulcerative colitis, but both were healthy at the time of the study. Two patients were taking prophylactic antibiotics throughout the study because of recurrent urinary tract infection. They remained on maintenance treatment throughout the study, and did not experience any recurrence ofvaginal candidosis. Compared with patients who had attended previously, more first time attenders were married and had a shorter history of disease. The 23 patients who had attended previously had made a total of 148 previous visits for recurrent vaginal candidosis in 648 patient months, which was equivalent to one recurrent attack a patient every 4-4 months.
OUTCOME OF TREATMENT
Of the 100 patients entering the study, 75 were followed up for more than six months. These 75 women consisted of 54 who continued maintenance treatment for longer than six months and 21 of the 22 who discontinued treatment before six months and returned with symptomatic recurrent candidosis. These 21 patients with recurrences were treated again and continued receiving maintenance treatment, but are evaluated in this study up to their recurrent episode only. They remained free of attacks, however, while receiving maintenance treatment. The one other of the Table 3 shows the detailed times to recurrence.
Fifty four patients persisted with prophylaxis for at least six months, and 25 of them continued treatment for 12 months. Seven of the 29 patients who discontinued treatment after six months attended again with a recurrence (symptoms and signs of vulvovaginitis and a positive culture for Candida spp). The mean time from stopping prophylaxis to experiencing clinical recurrence in this group was 3-9 months (tables 2 and 3). Two of the seven recurrences were caused by Candida glabrata, which was cultured at nine and 12 months after the patients' entry into the study.
Occasional irritation and discharge was reported at week 7 by five patients. All had negative cultures for Candida spp, but three had vulvitis. One further patient who remained symptomless while receiving maintenance treatment had a positive culture for C albicans at week 7, but no symptoms or signs ofvulvitis or vaginitis. This one apparent recolonisation during continuous maintenance treatment was no longer present at the 14 week assessment.
No patient, including the 25 women who continued prophylaxis for 12 months, developed symptomatic vaginal candidosis while receiving maintenance treatment.
ADVERSE REACTION
Mild irritation was reported by 21 patients, nine of whom discontinued prophylaxis before six months. All of these patients yielded negative cultures for Candida spp, and their symptoms cleared spontaneously or responded rapidly to external application of hydrocortisone (1 %) and miconazole (2%). Two patients reported an apparently allergic reaction to oral miconazole, which led to discontinuation of treatment. One other patient discontinued treatment Balsdon, Tobin before six months, having elected to receive specific treatment for any recurrence rather than persisting with prophylaxis.
Discussion
Numerous studies of the pathogenesis of vaginal candidosis have been undertaken, and many different theories have been proposed to explain why some women go on to develop recurrent disease.'9 Until the cause of recurrent vaginal candidosis is understood, however, managing patients with this unpleasant condition will rely heavily on antifungal treatment. The few published studies on drug treatment of patients suffering recurrences indicate that regular prophylactic treatment may offer a means of greatly reducing recurrences in such patients. 378 The first study that showed the efficacy of long term cyclical prophylaxis was reported by Davidson and Mould, who used topical clotrimazole treatment.3 They showed that prophylaxis reduced the attack rate of vaginal candidosis as long as the medication was given. The pattern of recurrent infection returned, however, once treatment was stopped. Similarly, Sobel has shown that cyclical prophylaxis with oral ketoconazole reduced the incidence of recurrences as long as it was given, but that candidosis soon returned after treatment was stopped.' Continuous daily prophylaxis with oral ketoconazole was also effective in preventing recurrent infection, but soon after treatment stopped nearly half the patients treated had recurrent candidosis.8
The study published here was designed to assess the suitability ofthe regular use ofmiconazole pessaries as a means of prophylaxis in women with recurrent vaginal candidosis. During maintenance treatment symptomatic vaginal candidosis did not occur, but relapse was common after prophylaxis stopped. Thus regular use of miconazole pessaries can reduce the recurrence rate, but prolonged prophylactic courses may not have any long lasting benefit after treatment stops.
Long term prophylaxis with any imidazole antifungal agent carries the theoretical risk that resistance to the drug may emerge during its prolonged use. Although future drug sensitivity studies are required, there are only four well substantiated reports of drug resistance to azole antifungals emerging during clinical use.`' The risk ofemergent resistance to the drug is therefore small and should not prevent further clinical studies of imidazole prophylaxis. Apart from some cases of minor irritation, the only side effects reported by our patients were two cases of allergic reaction. Such reactions are described in the manufacturer's data sheet (Gyno-Daktarin; Janssen Pharmaceutical, Wantage, Oxfordshire, England), and have also been
